SRF expression has been proved to drive the hepatocarcinogenesis 35, tumor aggressiveness 36, and sorafenib resistance 37 and YY1 induced cell proliferation 38 and tumor angiogenesis 39 in HCC. Here, YY1 is linked to neoplasm.